Grant: Op Gr: Spark Grants in Novel Technologies in Cancer Prevention & Early Detection
Université de Montréal
$150,000.00
Cancer steroidomics by tag-enhanced imaging mass spectrometry
EF 2020-21
Résumé
Steroids control growth, differentiation, reproduction and metabolism in plants and animals. In cancer, steroid biosynthesis goes out of control. Synthetic steroids are often used to treat cancer, related symptoms and chemotherapeutic side effects. Although spaciotemporal mapping of the distribution of steroids would enable unique potential for early diagnosis and therapeutic management of cancer and other diseases, no imaging tools exist for effective detection of steroids in biopsied tissue.
Imaging Mass Spectrometry (IMS) is a discerning tool for molecular histology, but except for abundant cholesterol, low in vivo concentrations inhibit steroid analysis in biopsied tissue. Our steroid-tagging agents enhance sensitivity in IMS and mitigate problems of low concentration and poor ionization. With goals of using steroid histology to diagnose early and monitor cancer, we propose to validate full-spectrum steroid-tagged IMS in biopsied tissue from five different kinds of cancers.
Our steroid-tagging agents enhance detection by IMS to effectively image a full spectrum of steroids within tissues. Best tags will be validated in human cancer tissue biopsies. The spatiotemporal levels of steroids known to be up- and down-regulated in cancer will be studied to detect early and itemize hallmarks of different stages of cancer. Sensitive full-spectrum steroid profiling in biopsied tissue would have major socioeconomic and healthcare benefits for enhancing diagnosis and treatment of this insidious disease.
Our expertise in medicinal chemistry, IMS analysis, and biomolecular and clinical research is well positioned to make a leap in cancer imaging. Our reagents and methods are designed to enable routine steroid-tagged IMS for accurate and early cancer diagnosis. Validation in cancer tissue will have major ramifications for studying dysregulated steroid signaling in a range of diseases and after exposure to cancer-causing contaminants in the environment.
Programme
Op Gr: Spark Grants in Novel Technologies in Cancer Prevention & Early Detection
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
436925
Name
Chaurand Pierre
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Cancer Society - National Office (Toronto); Brain Canada Foundation (Montreal, Québec)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Cancer steroidomics by tag-enhanced imaging mass spectrometry
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Op Gr: Spark Grants in Novel Technologies in Cancer Prevention & Early Detection
Keyworddelim
Cancer; Histology; Imaging Mass Spectrometry; Ms-Tag; Steroids; Tissue
Abstract
Steroids control growth, differentiation, reproduction and metabolism in plants and animals. In cancer, steroid biosynthesis goes out of control. Synthetic steroids are often used to treat cancer, related symptoms and chemotherapeutic side effects. Although spaciotemporal mapping of the distribution of steroids would enable unique potential for early diagnosis and therapeutic management of cancer and other diseases, no imaging tools exist for effective detection of steroids in biopsied tissue.
Imaging Mass Spectrometry (IMS) is a discerning tool for molecular histology, but except for abundant cholesterol, low in vivo concentrations inhibit steroid analysis in biopsied tissue. Our steroid-tagging agents enhance sensitivity in IMS and mitigate problems of low concentration and poor ionization. With goals of using steroid histology to diagnose early and monitor cancer, we propose to validate full-spectrum steroid-tagged IMS in biopsied tissue from five different kinds of cancers.
Our steroid-tagging agents enhance detection by IMS to effectively image a full spectrum of steroids within tissues. Best tags will be validated in human cancer tissue biopsies. The spatiotemporal levels of steroids known to be up- and down-regulated in cancer will be studied to detect early and itemize hallmarks of different stages of cancer. Sensitive full-spectrum steroid profiling in biopsied tissue would have major socioeconomic and healthcare benefits for enhancing diagnosis and treatment of this insidious disease.
Our expertise in medicinal chemistry, IMS analysis, and biomolecular and clinical research is well positioned to make a leap in cancer imaging. Our reagents and methods are designed to enable routine steroid-tagged IMS for accurate and early cancer diagnosis. Validation in cancer tissue will have major ramifications for studying dysregulated steroid signaling in a range of diseases and after exposure to cancer-causing contaminants in the environment.
Competitiondate
202010
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chaurand, Pierre
Approvedterm
1 an 0 mois
Cihrcontribution2
Breast Cancer Initiative~ $150,000~ $0~